Mineralys Therapeutics (MLYS) Retained Earnings (2022 - 2026)

Mineralys Therapeutics has reported Retained Earnings for 5 years, with the latest figure at -$496.5 million in Q1 2026.

• Quarterly Retained Earnings fell 44.03% year-over-year to -$496.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$496.5 million (down 44.03% YoY) and the FY2025 annual result came in at $1.1 billion, up 123.56% from the prior year.
• Retained Earnings eased to -$496.5 million in Q1 2026 per MLYS's latest filing, from $1.1 billion in the prior quarter.
• Over five years, Retained Earnings peaked at $1.1 billion in Q4 2025 and troughed at -$496.5 million in Q1 2026.
• A 5-year average of $191.5 million and a median of $155.8 million in 2022 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings jumped 840.45% in 2024, then tumbled 171.19% in 2025.
• Over 5 years, Retained Earnings stood at -$52.8 million in 2022, then jumped by 792.78% to $365.9 million in 2023, then soared by 34.96% to $493.8 million in 2024, then soared by 123.56% to $1.1 billion in 2025, then plunged by 144.98% to -$496.5 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$496.5 million, $1.1 billion, and $1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.